Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
The decision to discontinue the NN028-1801 trial is not due to any safety concerns. The trial was terminated as a result of a strategic decision by the sponsoring company.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage III melanoma
ECOG performance status 0-1
You may not be if
Signs of stage IV melanoma
Safety variables
Clareo Health | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
